Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral STL303 in Adults With Geographic Atrophy Secondary to AMD
NCT07606365Phase 2Recruiting
- Sponsor
- Sitala Bio
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in geographic atrophy (GA) (3 arms), sponsored by Sitala Bio. Primary endpoint: Reduction of rate of total EZ area loss at 52 weeks. Started Sep 2026; status: recruiting.
02
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07606365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606365.